Targeting epigenetic mechanisms may offer potential new therapies for people with developmental disorders including autism, researchers said today at the Society for Neuroscience meeting.
Efforts to ease the symptoms of autism are beginning to ramp up, with promising candidates in various stages of testing.
Treatment with the insulin-like growth factor (IGF) greatly improves the health of mouse models of Rett syndrome ― a regressive genetic disorder that causes mental retardation, seizures, and autistic features ― according to unpublished researched presented this morning at the Society for Neuroscience conference.
Research on mouse models published in the past year is paving the way to reversing the symptoms of some autism-related disorders, National Institute Health directors told a packed room of 80 reporters at the morning at the Society for Neuroscience conference.
In the late 1960s, as an undergraduate student in psychology at the University of California, Los Angeles, Cathy Lord spent a couple of hours a day teaching two young boys with autism.
Fragile X syndrome is a rare and devastating condition, and a risk factor for autism. New research suggesting the condition is reversible in mice has some wondering whether treatments for the syndrome ― and for some forms of autism ― could be on the horizon.
In 1982, Josh Huang was an impressionable young biology undergraduate at Shanghaiʼs FuDan University. Like some of his fellow Chinese students, he knew he wanted to be a neuroscientist, but with limited access to scientific journals, had no idea which big questions were then at the forefront of research.